Identification of biomarkers
The identification of new biomarker(s) related to FSHD will facilitate the implementation of smaller and shorter clinical trials; better patient selection and stratification and finally a better evaluation of treatment options for patients. Such biomarkers could be an added value to the development of unique software in the field of personalized medicine to help medical decision-making adapted to patients with FSHD.
The clinical studies we have conducted have led us to set up a specialized and personalized consultation in order to analyze the long-term effects of antioxidant intake adjusted to each patient’s specific analyses, on muscle function and to the development of automated medical decision support software implementing the rules for antioxidant supplementation dosage adapted to the patient’s profile.
All the fundamental, functional, clinical and biological data will be supported by new analysis methods in bioinformatics, biostatistics and mathematical modelling.